In vitro Antimicrobial Activity and Dose Optimization of Eravacycline and Other Tetracycline Derivatives Against Levofloxacin-Non-Susceptible and/or Trimethoprim-Sulfamethoxazole-Resistant Stenotrophomonas maltophilia

References

• Perez F, Adachi J, Bonomo RA. Antibiotic-resistant gram-negative bacterial infections in patients with cancer. Clin Infect Dis. 2014;59(Suppl 5):S335–339. doi:10.1093/cid/ciu612
   PubMed Web of Science ®Google Scholar
• Chang YT, Lin CY, Chen YH, Hsueh PR. Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic options. Front Microbiol. 2015;6:893. doi:10.3389/fmicb.2015.00893
   PubMed Web of Science ®Google Scholar
• Mojica MF, Rutter JD, Taracila M, et al. Population structure, molecular epidemiology, and β-lactamase diversity among stenotrophomonas maltophilia isolates in the United States. mBio. 2019;10(4). doi:10.1128/mBio.00405-19
   PubMed Web of Science ®Google Scholar
• Mojica MF, Ouellette CP, Leber A, et al. Successful treatment of bloodstream infection due to metallo-β-lactamase-producing Stenotrophomonas maltophilia in a renal transplant patient. Antimicrob Agents Chemother. 2016;60(9):5130–5134. doi:10.1128/AAC.00264-16
   PubMed Web of Science ®Google Scholar
• Hu L-F, Xu X-H, Li H-R, et al. Surveillance of antimicrobial susceptibility patterns among Stenotrophomonas maltophilia isolated in China during the 10-year period of 2005–2014. J Chemother. 2018;30(1):25–30. doi:10.1080/1120009X.2017.1378834
   PubMed Web of Science ®Google Scholar
• Ko JH, Kang CI, Cornejo-Juárez P, et al. Fluoroquinolones versus trimethoprim-sulfamethoxazole for the treatment of Stenotrophomonas maltophilia infections: a systematic review and meta-analysis. Clin Microbiol Infect. 2019;25(5):546–554. doi:10.1016/j.cmi.2018.11.008
   PubMed Web of Science ®Google Scholar
• Nys C, Cherabuddi K, Venugopalan V, Klinker KP. Clinical and microbiologic outcomes in patients with monomicrobial stenotrophomonas maltophilia infections. Antimicrob Agents Chemother. 2019;63(11). doi:10.1128/AAC.00788-19
   PubMed Web of Science ®Google Scholar
• Sader HS, Castanheira M, Mendes RE, Flamm RK. Frequency and antimicrobial susceptibility of Gram-negative bacteria isolated from patients with pneumonia hospitalized in ICUs of US medical centres (2015–17). J Antimicrob Chemother. 2018;73(11):3053–3059. doi:10.1093/jac/dky279
   PubMed Web of Science ®Google Scholar
• Biagi M, Tan X, Wu T, et al. Activity of potential alternative treatment agents for stenotrophomonas maltophilia isolates nonsusceptible to levofloxacin and/or trimethoprim-sulfamethoxazole. J Clin Microbiol. 2020;58(2). doi:10.1128/JCM.01603-19
   PubMed Web of Science ®Google Scholar
• Flamm RK, Shortridge D, Castanheira M, Sader HS, Pfaller MA. In vitro activity of minocycline against U.S. isolates of Acinetobacter baumannii-Acinetobacter calcoaceticus species complex, stenotrophomonas maltophilia, and Burkholderia cepacia complex: results from the SENTRY antimicrobial surveillance program, 2014 to 2018. Antimicrob Agents Chemother. 2019;63(11):1.
   Web of Science ®Google Scholar
• Morrissey I, Olesky M, Hawser S, et al. In vitro activity of eravacycline against gram-negative bacilli isolated in clinical laboratories worldwide from 2013 to 2017. Antimicrob Agents Chemother. 2020;64(3):1.
   Web of Science ®Google Scholar
• Zhanel GG, Cheung D, Adam H, et al. Review of eravacycline, a novel fluorocycline antibacterial agent. Drugs. 2016;76(5):567–588. doi:10.1007/s40265-016-0545-8
   PubMed Web of Science ®Google Scholar
• Zidaru A, Phe K, Lasco TM, Tam VH. An integrated approach to evaluate different tetracycline derivatives for formulary decisions. Am J Health Syst Pharm. 2022;79(6):467–471. doi:10.1093/ajhp/zxab451
   PubMed Web of Science ®Google Scholar
• Baidya A, Kodan P, Fazal F, et al. Stenotrophomonas maltophilia: more than just a colonizer! Indian J Crit Care Med. 2019;23(9):434–436. doi:10.5005/jp-journals-10071-23241
   PubMed Web of Science ®Google Scholar
• Pathmanathan A, Waterer GW. Significance of positive Stenotrophomonas maltophilia culture in acute respiratory tract infection. Eur Respir J. 2005;25(5):911–914. doi:10.1183/09031936.05.00096704
   PubMed Web of Science ®Google Scholar
• Kwa AL, Low JG, Lim TP, Leow PC, Kurup A, Tam VH. Independent predictors for mortality in patients with positive Stenotrophomonas maltophilia cultures. Ann Acad Med Singapore. 2008;37(10):826–830. doi:10.47102/annals-acadmedsg.V37N10p826
   PubMed Web of Science ®Google Scholar
• Oladunjoye OO, Oladunjoye AO, Oladiran O, Donato AA. Stenotrophomonas maltophilia infection in a patient with acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD): a colonizer or true infection? Am J Case Rep. 2020;21:e924577. doi:10.12659/AJCR.924577
   PubMed Web of Science ®Google Scholar
• Erb CT, Patel B, Orr JE, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia. Ann Am Thorac Soc. 2016;13(12):2258–2260. doi:10.1513/AnnalsATS.201608-641CME
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. CLSI document M100-Ed32. Wayne, PA: Clinical and Laboratory Standards Institute; 2022.
   Google Scholar
• Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. CLSI document M07-Ed11. Wayne, PA: Clinical and Laboratory Standards Institute; 2018.
   Google Scholar
• Wyeth Pharmaceuticals Inc. Tygacil^® (Tigecycline) for Injection. Philadelphia (PA): Wyeth Pharmaceuticals Inc; 2013.
   Google Scholar
• Zhou Y, Xu P, Li H, et al. Population pharmacokinetics and exposure-response analysis of tigecycline in patients with hospital-acquired pneumonia. Br J Clin Pharmacol. 2021;87(7):2838–2846. doi:10.1111/bcp.14692
   PubMed Web of Science ®Google Scholar
• Bhavnani SM, Rubino CM, Hammel JP, et al. Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecycline. Antimicrob Agents Chemother. 2012;56(2):1065–1072. doi:10.1128/AAC.01615-10
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Takano K, Matsuyama N, et al. Pharmacokinetic characteristics of minocycline in debilitated elderly patients. Am J Ther. 1999;6(3):157–160. doi:10.1097/00045391-199905000-00006
   PubMedGoogle Scholar
• Maaland MG, Papich MG, Turnidge J, Guardabassi L. Pharmacodynamics of doxycycline and tetracycline against Staphylococcus pseudintermedius: proposal of canine-specific breakpoints for doxycycline. J Clin Microbiol. 2013;51(11):3547–3554. doi:10.1128/JCM.01498-13
   PubMed Web of Science ®Google Scholar
• Andes D, Craig W. Pharmacokinetics and Pharmacodynamics of Tetracyclines. In: Nightingale CH, editor. Antimicrobial Pharmacodynamics in Theory and Clinical Practice. 2nd ed. Informa Healthcare; 2007:267–278.
   Google Scholar
• Mouton JW, Dudley MN, Cars O, Derendorf H, Drusano GL. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J Antimicrob Chemother. 2005;55(5):601–607. doi:10.1093/jac/dki079
   PubMed Web of Science ®Google Scholar
• Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America guidance on the treatment of AmpC β-lactamase-producing Enterobacterales, carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia infections. Clin Infect Dis. 2022;74(12):2089–2114. doi:10.1093/cid/ciab1013
   PubMed Web of Science ®Google Scholar
• Lee YR, Burton CE. Eravacycline, a newly approved fluorocycline. Eur J Clin Microbiol Infect Dis. 2019;38(10):1787–1794. doi:10.1007/s10096-019-03590-3
   PubMed Web of Science ®Google Scholar
• McCarthy MW. Clinical pharmacokinetics and pharmacodynamics of eravacycline. Clin Pharmacokinet. 2019;58(9):1149–1153. doi:10.1007/s40262-019-00767-z
   PubMed Web of Science ®Google Scholar
• Thabit AK, Monogue ML, Newman JV, Nicolau DP. Assessment of in vivo efficacy of eravacycline against Enterobacteriaceae exhibiting various resistance mechanisms: a dose-ranging study and pharmacokinetic/pharmacodynamic analysis. Int J Antimicrob Agents. 2018;51(5):727–732. doi:10.1016/j.ijantimicag.2018.01.001
   PubMed Web of Science ®Google Scholar
• Solomkin J, Evans D, Slepavicius A, et al. Assessing the efficacy and safety of eravacycline vs ertapenem in complicated intra-abdominal infections in the Investigating Gram-Negative Infections Treated With Eravacycline (IGNITE 1) trial: a randomized clinical trial. JAMA Surg. 2017;152(3):224–232. doi:10.1001/jamasurg.2016.4237
   PubMed Web of Science ®Google Scholar
• Solomkin JS, Gardovskis J, Lawrence K, et al. IGNITE4: results of a Phase 3, Randomized, Multicenter, Prospective Trial of Eravacycline vs Meropenem in the Treatment of Complicated Intraabdominal Infections. Clin Infect Dis. 2019;69(6):921–929. doi:10.1093/cid/ciy1029
   PubMed Web of Science ®Google Scholar
• Connors KP, Housman ST, Pope JS, et al. Phase I, open-label, safety and pharmacokinetic study to assess bronchopulmonary disposition of intravenous eravacycline in healthy men and women. Antimicrob Agents Chemother. 2014;58(4):2113–2118. doi:10.1128/AAC.02036-13
   PubMed Web of Science ®Google Scholar
• Newman JV, Zhou J, Izmailyan S, Tsai L. Randomized, double-blind, placebo-controlled studies of the safety and pharmacokinetics of single and multiple ascending doses of eravacycline. Antimicrob Agents Chemother. 2018;62(11). doi:10.1128/AAC.01174-18
   Web of Science ®Google Scholar
• Weiss WJ, Pulse M, Renick P, et al. Efficacy of fluorocyclines TP-434 in the neutropenic thigh infection model is predicted by AUC/MIC. Poster presented at: 50th Annual interscience conference on antimicrobial agents and chemotherapy; Boston; 2010.
   Google Scholar
• Watanabe A, Anzai Y, Niitsuma K, Saito M, Yanase K, Nakamura M. Penetration of minocycline hydrochloride into lung tissue and sputum. Chemotherapy. 2001;47(1):1–9. doi:10.1159/000048494
   PubMed Web of Science ®Google Scholar
• Zhou J, Ledesma KR, Chang KT, Abodakpi H, Gao S, Tam VH. Pharmacokinetics and pharmacodynamics of minocycline against Acinetobacter baumannii in a neutropenic murine pneumonia model. Antimicrob Agents Chemother. 2017;61(5):1.
   Web of Science ®Google Scholar
• Petraitis V, Petraitiene R, Maung BBW, et al. Pharmacokinetics and comprehensive analysis of the tissue distribution of eravacycline in rabbits. Antimicrob Agents Chemother. 2018;62(9). doi:10.1128/AAC.00275-18
   PubMed Web of Science ®Google Scholar
• Cornely OA, Arenz D, Barraud O, et al. Phase I study to evaluate the safety and pharmacokinetics of single and multiple ascending doses of intravenous minocycline in healthy adult subjects. Poster presented at: IDWeek 2018; San Francisco, CA; 2018.
   Google Scholar